Fig. 1.
Fig. 1. B-cell lymphopenia following rituximab treatment. / Median and individual peripheral blood B-cell numbers in recipients of a TCD allo-SCT with EBV-DNA more than or equal to 1000 geq/mL before and after preemptive rituximab (PE-therapy) given at day 0 (dashed line denotes detection limit of assay; horizontal solid lines indicate median value).

B-cell lymphopenia following rituximab treatment.

Median and individual peripheral blood B-cell numbers in recipients of a TCD allo-SCT with EBV-DNA more than or equal to 1000 geq/mL before and after preemptive rituximab (PE-therapy) given at day 0 (dashed line denotes detection limit of assay; horizontal solid lines indicate median value).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal